Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2059PDF: 1653HTML: 360 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3557PDF: 870HTML: 6702 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3724PDF: 1640HTML: 11548Figures Haase: 191 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3977PDF: 1035HTML: 3575Untitled: 172Cneo. Fig.1: 108Untitled: 98Untitled: 123Untitled: 127 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1343HTML: 382PDF: 810 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2777PDF: 1000HTML: 5509 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
2889PDF: 871HTML: 1571 -
A MULTICENTER EXPERIENCE FROM LEBANON IN CHILDHOOD AND ADOLESCENT ACUTE MYELOID LEUKEMIA:HIGH RATE OF EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA.
2051PDF: 1106HTML: 7684cover letter paper final AML: 211 -
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
4610PDF: 1305HTML: 1901Untitled: 178Untitled: 174 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4267PDF: 1743HTML: 1100 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2553PDF: 795HTML: 5200 -
OLDER ADULTS WITH PH NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: A MONOCENTRIC EXPERIENCE ON CONSECUTIVE PATIENTS AGED MORE THAN 55 YEARS Older Adults with Ph Negative Acute Lymphoblastic Leukemia
1272PDF: 557Suppl. Files: 341HTML: 135 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
1489PDF: 525HTML: 263 -
CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.
3118PDF: 885HTML: 1528Fig.1 CHL-R paper: 209Fig 2 CHL-R paper: 232 -
DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES.
4751PDF: 1782HTML: 2119 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3489PDF: 1536HTML: 69 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
8988PDF: 6029HTML: 87929Fig.1b: 178Fig.1c: 180Fig.2a: 171Fig.2b: 170Fig.4: 183Fig.2c: 179Fig.3: 177Tab.1: 222Tab.2: 202Tab.3: 184Tab.4: 217Fig1a: 175 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1163PDF: 1051HTML: 184 -
TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment TDT POSITIVE HIGH-GRADE LYMPHOMA WITH MYC, BCL2 AND BCL6 REARRANGEMENTS.
1665PDF: 749HTML: 481 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1752PDF: 960HTML: 134 -
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
933PDF: 1199HTML: 99 -
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1204PDF: 751HTML: 304 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
2804PDF: 1214HTML: 2686Figure 1: 166 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1617PDF: 1164HTML: 191 -
Aberrant acquisition of T-cell associated markers in plasma cell neoplasms: An aggressive disease with extramedullary involvement and very short survival Aberrant T markers on malignant plasma cells
1506PDF: 384HTML: 200







